Stocks Health care LRMR
NASDAQ · Health careLarimar Therapeutics, Inc. (LRMR)
It posted a net loss of $172.6M. In fiscal 2025 capital spending exceeded operating cash flow by $113.3M. At June 30, 2026 it held $92.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Larimar Therapeutics, Inc. does
Larimar Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LRMR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$165.7M | n/a | -$113.3M |
| 2024 | n/a | -$80.6M | -$1.32 | -$71.3M |
| 2023 | n/a | -$36.9M | -$0.84 | -$33.6M |
| 2022 | n/a | -$35.4M | -$1.37 | -$27.7M |
| 2021 | n/a | -$50.6M | -$2.95 | -$42.4M |
| 2020 | n/a | -$42.5M | -$3.57 | -$42.3M |
Latest SEC filings
What Larimar Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- June 29, 2026Other event 8-K
- May 19, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- May 14, 2026
- April 30, 2026Passive stake changed SCHEDULE 13G/A
- April 20, 2026
- April 20, 2026Proxy statement DEF 14A
Questions about LRMR
What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LRMR.
Is Larimar Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $172.6M.
When did Larimar Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026.
Similar companies
Follow LRMR
Get an email when Larimar Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow LRMR: get an email when it filesWhere the numbers come from
Financial figures are the values Larimar Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.